Investment case
Ionis Pharmaceuticals, Inc.
IONS · 14 developments mapped · last assessed 2026-09-25
Market Ontology has mapped 14 macro, policy, and market developments to Ionis Pharmaceuticals, Inc. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for IONS yet, so no modelled value is shown. The IONS valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IONS on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
Direct clinical trial success leading to potential regulatory submission and future commercialization. Increased probability of milestone payments and royalty streams.
· Moves probability of success for pipeline assets, peak sales estimates for ulefnersen and sefaxersen, discount rate (due to reduced risk)
- Main threat
Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen
Direct impact from clinical trial failures, reducing future revenue potential and increasing R&D risk perception.
· Moves probability of success for pipeline assets, peak sales estimates for pelacarsen and eplontersen, discount rate reflecting increased risk
- Open question
Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
Increased investor attention on neurodegenerative drug development, potential for partnership or competitive landscape shifts.
· Moves probability of success pipeline, peak sales estimates
What changed, by assumption
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies
- 2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs
- 2026-09-23Roche to Acquire Ionis Pharmaceuticals, Inc.
- 2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks
- 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-23 | Revenue | Bullish | Positive Phase 3 interim data triggers eligibility for regulatory and sales milestone payments and future royalties from partner Roche. | 0.85 |
| 2026-09-07 | Revenue | Bearish | Phase 3 Lp(a)HORIZON study for pelacarsen did not meet primary endpoint, likely impacting future royalty and milestone revenue expectations from partner Novartis. | 0.95 |
| 2026-09-07 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
| 2026-09-07 | Revenue | Bearish | Phase 3 Lp(a)HORIZON study for pelacarsen did not meet its primary endpoint, likely impacting future royalty and milestone revenue expectations from partner Novartis. | 0.95 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share | mixed | 3-12m | 0.20 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | Bullish | 1-3m | 0.90 |
| 2026-09-24 | Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease | Bullish | 1-3m | 0.90 |
| 2026-09-24 | Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies | Bullish | 1-3m | 0.90 |
| 2026-09-24 | Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs | Bullish | 1-3m | 0.90 |
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | Bullish | 1-5d | 0.90 |
| 2026-09-21 | Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen | Bearish | 1-3m | 0.90 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | Bearish | 1-3m | 0.90 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Bearish | 1-3m | 0.90 |
| 2026-09-21 | Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks | Bearish | 3-12m | 0.90 |
| 2026-09-21 | Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks | Bearish | 1-3m | 0.90 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Bearish | 1-3m | 0.60 |